| 000 | 01873 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514225944.0 | ||
| 264 | 0 | _c20050712 | |
| 008 | 200507s 0 0 eng d | ||
| 022 | _a1530-891X | ||
| 024 | 7 |
_a10.4158/EP.11.2.135 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, Yong Q | |
| 245 | 0 | 0 |
_aLife-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic hepatitis C. _h[electronic resource] |
| 260 |
_bEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists _c |
||
| 300 |
_a135-9 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Clinical Conference; Journal Article | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aAntithyroid Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 | _aPolyethylene Glycols |
| 650 | 0 | 4 |
_aPropranolol _xtherapeutic use |
| 650 | 0 | 4 |
_aPropylthiouracil _xtherapeutic use |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 |
_aRibavirin _xadverse effects |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aThyrotoxicosis _xchemically induced |
| 700 | 1 | _aWang, Xiangbing | |
| 700 | 1 | _aMurthy, Meena S | |
| 700 | 1 | _aAgarwala, Sumon | |
| 773 | 0 |
_tEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists _gvol. 11 _gno. 2 _gp. 135-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4158/EP.11.2.135 _zAvailable from publisher's website |
| 999 |
_c15563694 _d15563694 |
||